OKYO Pharma Ltd ADR (OKYO) - Net Assets

Latest as of September 2025: $-3.42 Million USD

Based on the latest financial reports, OKYO Pharma Ltd ADR (OKYO) has net assets worth $-3.42 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($4.64 Million) and total liabilities ($8.06 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check OKYO Pharma Ltd ADR liquidity resilience to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	$-3.42 Million
% of Total Assets	-73.54%
Annual Growth Rate	N/A
5-Year Change	-204.33%
10-Year Change	-117.34%
Growth Volatility	79.95

OKYO Pharma Ltd ADR - Net Assets Trend (2008–2025)

This chart illustrates how OKYO Pharma Ltd ADR's net assets have evolved over time, based on quarterly financial data. Also explore OKYO total assets for the complete picture of this company's asset base.

Annual Net Assets for OKYO Pharma Ltd ADR (2008–2025)

The table below shows the annual net assets of OKYO Pharma Ltd ADR from 2008 to 2025. For live valuation and market cap data, see OKYO stock market capitalisation.

Year	Net Assets	Change
2025-03-31	$-5.55 Million	+5.61%
2024-03-31	$-5.88 Million	-186.36%
2023-03-31	$-2.05 Million	-169.66%
2022-03-31	$2.95 Million	-44.59%
2021-03-31	$5.32 Million	+3905.04%
2020-03-31	$-139.80K	-141.96%
2019-03-31	$333.14K	-82.62%
2018-03-31	$1.92 Million	-93.03%
2017-03-31	$27.50 Million	-14.08%
2016-03-31	$32.00 Million	-5.59%
2015-03-31	$33.90 Million	-27.82%
2014-03-31	$46.96 Million	+4.32%
2013-03-31	$45.02 Million	+8.83%
2012-03-31	$41.36 Million	+158.33%
2011-03-31	$16.01 Million	-70.38%
2010-03-31	$54.05 Million	+41.57%
2009-03-31	$38.18 Million	+39.06%
2008-03-31	$27.46 Million	--

Equity Component Analysis

This analysis shows how different components contribute to OKYO Pharma Ltd ADR's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 14005041154.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (March 2025)

Component	Amount	Percentage
Common Stock	$146.72 Million	%
Other Comprehensive Income	$-11.47 Million	%
Other Components	$2.23 Million	%
Total Equity	$-5.55 Million	100.00%

OKYO Pharma Ltd ADR Competitors by Market Cap

The table below lists competitors of OKYO Pharma Ltd ADR ranked by their market capitalization.

Company	Market Cap
Susco Public Company Limited BK:SUSCO	$59.81 Million
U-Tech Media Corp TW:3050	$59.81 Million
Cactus Acquisition Corp 1 Ltd NASDAQ:CCTS	$59.83 Million
Kuangli Photoelectric Technology Co Ltd TW:6431	$59.84 Million
The Investment Trust Of India Limited NSE:THEINVEST	$59.80 Million
Ailleron S.A. WAR:ALL	$59.78 Million
Choheung KO:002600	$59.77 Million
Bali Bintang Sejahtera Tbk PT JK:BOLA	$59.77 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in OKYO Pharma Ltd ADR's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from -5,879,582 to -5,549,555, a change of 330,027.
Net loss of 4,706,292 reduced equity.
New share issuances of 1,705,742 increased equity.
Other comprehensive income decreased equity by 158,973.
Other factors increased equity by 3,489,550.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	$-4.71 Million	-84.8%
Share Issuances	$1.71 Million	+30.74%
Other Comprehensive Income	$-158.97K	-2.86%
Other Changes	$3.49 Million	+62.88%
Total Change	$-	%

Book Value vs Market Value Analysis

This analysis compares OKYO Pharma Ltd ADR's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2008-03-31	$0.49	$1.59	x
2009-03-31	$1.27	$1.59	x
2010-03-31	$12.62	$1.59	x
2011-03-31	$3.74	$1.59	x
2012-03-31	$9.65	$1.59	x
2013-03-31	$10.16	$1.59	x
2014-03-31	$10.14	$1.59	x
2015-03-31	$5.41	$1.59	x
2016-03-31	$5.46	$1.59	x
2017-03-31	$4.69	$1.59	x
2018-03-31	$0.33	$1.59	x
2019-03-31	$0.04	$1.59	x
2020-03-31	$-0.02	$1.59	x
2021-03-31	$0.51	$1.59	x
2022-03-31	$0.20	$1.59	x
2023-03-31	$-0.09	$1.59	x
2024-03-31	$-0.20	$1.59	x
2025-03-31	$-0.14	$1.59	x

Capital Efficiency Dashboard

This dashboard shows how efficiently OKYO Pharma Ltd ADR utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 0.00%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 0.00%
• Asset Turnover: 0.00x
• Equity Multiplier: 0.00x
Recent ROE (0.00%) is above the historical average (-179.60%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2008	-10.83%	0.00%	0.00x	1.01x	$-5.72 Million
2009	37.54%	0.00%	0.00x	1.00x	$10.52 Million
2010	23.44%	0.00%	0.00x	1.00x	$7.27 Million
2011	-10.10%	0.00%	0.00x	1.00x	$-3.22 Million
2012	-11.62%	0.00%	0.00x	1.02x	$-8.94 Million
2013	-10.75%	0.00%	0.00x	1.00x	$-9.34 Million
2014	-29.70%	0.00%	0.00x	1.01x	$-18.64 Million
2015	-24.35%	0.00%	0.00x	1.00x	$-11.64 Million
2016	-2.56%	0.00%	0.00x	1.01x	$-4.02 Million
2017	-0.88%	0.00%	0.00x	1.01x	$-2.99 Million
2018	-1476.35%	0.00%	0.00x	1.05x	$-28.49 Million
2019	-1469.36%	0.00%	0.00x	2.28x	$-4.93 Million
2020	0.00%	0.00%	0.00x	0.00x	$-1.53 Million
2021	-63.05%	0.00%	0.00x	1.33x	$-3.89 Million
2022	-184.26%	0.00%	0.00x	1.46x	$-5.73 Million
2023	0.00%	0.00%	0.00x	0.00x	$-13.07 Million
2024	0.00%	0.00%	0.00x	0.00x	$-16.24 Million
2025	0.00%	0.00%	0.00x	0.00x	$-4.15 Million

Industry Comparison

This section compares OKYO Pharma Ltd ADR's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $173,740,057
Average return on equity (ROE) among peers: -43.94%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
OKYO Pharma Ltd ADR (OKYO)	$-3.42 Million	-10.83%	N/A	$59.80 Million
Aardvark Therapeutics, Inc. Common Stock (AARD)	$-27.92 Million	0.00%	0.00x	$118.88 Million
Abcellera Biologics Inc (ABCL)	$1.06 Billion	-15.42%	0.29x	$1.07 Billion
Abeona Therapeutics Inc (ABEO)	$1.69 Million	20.23%	0.26x	$292.09 Million
Acumen Pharmaceuticals Inc (ABOS)	$70.43 Million	-172.28%	0.74x	$171.87 Million
Abpro Holdings, Inc. (ABP)	$-85.14 Million	0.00%	0.00x	$448.19K
Absci Corp (ABSI)	$-41.16 Million	0.00%	0.00x	$345.85 Million
Arbutus Biopharma Corp (ABUS)	$38.29 Million	-30.60%	0.11x	$840.56 Million
ABVC Biopharma Inc (ABVC)	$60.67K	-43.96%	0.04x	$26.41 Million
Abivax SA American Depositary Shares (ABVX)	$25.93 Million	-163.70%	3.21x	$9.33 Billion
ACADIA Pharmaceuticals Inc (ACAD)	$699.13 Million	-33.65%	0.12x	$3.74 Billion

About OKYO Pharma Ltd ADR

NASDAQ:OKYO USA Biotechnology

Market Cap

$59.80 Million

Market Cap Rank

#21201 Global

#4534 in USA

Share Price

$1.59

Change (1 day)

-1.85%

52-Week Range

$1.34 - $3.27

All Time High

$3.74